GlassScriptPhysician profile
Michael Kenneth Watterson
NPI 1477548584
$11,502.80
in general payments reported to CMS, 2019-2025
30 companies · $1,326 in 2025
The $1,326 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,538 · 2020: $1,380 · 2021: $1,172 · 2022: $53.52 · 2023: $3,332 · 2024: $702 · 2025: $1,326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,760 · Food and Beverage: $2,487 · Travel and Lodging: $113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,760.00 |
| Food and Beverage | $2,486.78 |
| Travel and Lodging | $112.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $3,761.08 | 2019-2024 | Bimzelx, Cimzia |
| Amgen INC. | $1,633.50 | 2019-2025 | Krystexxa, Otezla, Enbrel |
| Abbvie INC. | $1,078.90 | 2019-2025 | |
| Pfizer INC. | $905.50 | 2019-2025 | |
| Janssen Biotech, INC. | $750.11 | 2019-2024 | Remicade, Simponi Aria, Tremfya |
| Lilly USA, LLC | $703.29 | 2019-2025 | Zepbound, Taltz |
| Glaxosmithkline, LLC. | $440.18 | 2019-2025 | Benlysta |
| Novartis Pharmaceuticals Corporation | $422.27 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $359.72 | 2019-2021 | |
| Horizon Therapeutics Plc | $322.39 | 2019-2023 | Krystexxa |
| Regeneron Healthcare Solutions, INC. | $204.81 | 2019 | |
| Genzyme Corporation | $124.56 | 2020-2021 | |
| Celgene Corporation | $114.35 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.74 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $83.71 | 2021-2025 | Saphnelo |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $75.16 | 2019-2022 | |
| Radius Health, INC. | $51.36 | 2021 | |
| Sobi, INC | $49.45 | 2019 | |
| Antares Pharma, INC. | $47.71 | 2019 | |
| Hikma Pharmaceuticals USA | $44.26 | 2019 | |
| Janssen Scientific Affairs, LLC | $43.76 | 2019 | |
| Mallinckrodt Hospital Products INC. | $41.75 | 2021 | |
| Alexion Pharmaceuticals, INC. | $28.84 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $24.14 | 2019 | |
| Sanofi-Aventis U.S. LLC | $23.62 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $21.93 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $18.50 | 2021 | |
| Fresenius Kabi USA, LLC | $15.04 | 2024 | Idacio |
| Mallinckrodt Enterprises LLC | $14.20 | 2019 | |
| Zyla Life Sciences, INC. | $10.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Watterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.